<table id="table18" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 18: The Effect of Varying Gastric Administration Conditions on the C<sub>max</sub> and AUC of Posaconazole Oral Suspension in Healthy Volunteers<footnote>In 5 subjects, the C<sub>max</sub> and AUC decreased substantially (range: -27% to -53% and  -33% to -51%, respectively) when Noxafil was administered via an NG tube compared to when Noxafil was administered orally. It is recommended to closely monitor patients for breakthrough fungal infections when Noxafil is administered via an NG tube because a lower plasma exposure may be associated with an increased risk of treatment failure.</footnote>
</caption>
<col align="left" valign="middle" width="35%"></col>
<col align="left" valign="middle" width="25%"></col>
<col align="center" valign="middle" width="20%"></col>
<col align="center" valign="middle" width="20%"></col>
<thead>
<tr>
<th align="center" stylecode="Lrule Rrule" valign="bottom">Study Description</th>
<th align="center" stylecode="Rrule" valign="bottom">Administration Arms</th>
<th stylecode="Rrule">Change in C<sub>max</sub>
<br/>(ratio estimate<footnote id="t17f1">Ratio Estimate is the ratio of coadministered drug plus posaconazole to coadministered drug alone for C<sub>max</sub> or AUC.</footnote>;<br/>90% CI of the ratio estimate)</th>
<th stylecode="Rrule">Change in AUC<br/>(ratio estimate<footnoteref idref="t17f1"></footnoteref>;<br/>90% CI of the ratio estimate)</th>
</tr>
</thead>
<tbody>
<tr stylecode="Botrule">
<td rowspan="3" stylecode="Lrule Rrule">400-mg single dose with a high-fat meal relative to fasted state (n=12)<br/>
</td>
<td stylecode="Rrule">5 minutes before high-fat meal</td>
<td stylecode="Rrule">↑96%<br/>(1.96; 1.48-2.59)</td>
<td stylecode="Rrule">↑111%<br/>(2.11; 1.60-2.78)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Rrule">During high-fat meal</td>
<td align="center" stylecode="Rrule">↑339%<br/>(4.39; 3.32-5.80)</td>
<td stylecode="Rrule">↑382%<br/>(4.82; 3.66-6.35)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Rrule">20 minutes after high-fat meal</td>
<td align="center" stylecode="Rrule">↑333%<br/>(4.33; 3.28-5.73)</td>
<td stylecode="Rrule">↑387%<br/>(4.87; 3.70-6.42)</td>
</tr>
<tr stylecode="Botrule">
<td rowspan="2" stylecode="Lrule Rrule">400 mg BID and 200 mg QID for 7 days in fasted state and with liquid nutritional supplement (BOOST<sup>®</sup>) (n=12)</td>
<td stylecode="Rrule">400 mg BID with BOOST</td>
<td stylecode="Rrule">↑65%<br/>(1.65; 1.29-2.11)</td>
<td stylecode="Rrule">↑66%<br/>(1.66; 1.30-2.13)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Rrule">200 mg QID with BOOST</td>
<td align="center" stylecode="Rrule">No Effect</td>
<td stylecode="Rrule">No Effect</td>
</tr>
<tr stylecode="Botrule">
<td rowspan="2" stylecode="Lrule Rrule">Divided daily dose from 400 mg BID to 200 mg QID for 7 days regardless of fasted conditions or with BOOST (n=12)</td>
<td stylecode="Rrule">Fasted state</td>
<td stylecode="Rrule">↑136%<br/>(2.36; 1.84-3.02)</td>
<td stylecode="Rrule">↑161%<br/>(2.61; 2.04-3.35)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Rrule">With BOOST</td>
<td align="center" stylecode="Rrule">↑137%<br/>(2.37; 1.86-3.04)</td>
<td stylecode="Rrule">↑157%<br/>(2.57; 2.00-3.30)</td>
</tr>
<tr stylecode="Botrule">
<td rowspan="2" stylecode="Lrule Rrule">400-mg single dose with carbonated acidic beverage (ginger ale) and/or proton pump inhibitor (esomeprazole) (n=12)</td>
<td stylecode="Rrule">Ginger ale</td>
<td stylecode="Rrule">↑92%<br/>(1.92; 1.51-2.44)</td>
<td stylecode="Rrule">↑70%<br/>(1.70; 1.43-2.03)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Rrule">Esomeprazole</td>
<td align="center" stylecode="Rrule">↓32%<br/>(0.68; 0.53-0.86)</td>
<td stylecode="Rrule">↓30%<br/>(0.70; 0.59-0.83)</td>
</tr>
<tr stylecode="Botrule">
<td rowspan="2" stylecode="Lrule Rrule">400-mg single dose with a prokinetic agent (metoclopramide 10 mg TID for 2 days) + BOOST or an antikinetic agent (loperamide 4-mg single dose) + BOOST (n=12)</td>
<td stylecode="Rrule">With metoclopramide + BOOST</td>
<td stylecode="Rrule">↓21%<br/>(0.79; 0.72-0.87)</td>
<td stylecode="Rrule">↓19%<br/>(0.81; 0.72-0.91)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Rrule">With loperamide + BOOST</td>
<td align="center" stylecode="Rrule">↓3%<br/>(0.97; 0.88-1.07)</td>
<td stylecode="Rrule">↑11%<br/>(1.11; 0.99-1.25)</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">400-mg single dose either orally with BOOST or via an NG tube with BOOST (n=16)</td>
<td stylecode="Rrule">Via NG tube<footnote>NG = nasogastric</footnote>
</td>
<td stylecode="Rrule">↓19%<br/>(0.81; 0.71-0.91)</td>
<td stylecode="Rrule">↓23%<br/>(0.77; 0.69-0.86)</td>
</tr>
</tbody>
</table>